Interstitial Lung Disease and Sarcoidosis

Michelle Sharp; Ali M Mustafa; Naima Farah; Catherine A Bonham

doi:10.1016/j.ccm.2023.06.003

Interstitial Lung Disease and Sarcoidosis

Clin Chest Med. 2023 Sep;44(3):575-584. doi: 10.1016/j.ccm.2023.06.003.

Authors

Michelle Sharp¹, Ali M Mustafa², Naima Farah³, Catherine A Bonham³

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. Electronic address: msharp5@jh.edu.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA.
³ Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, University of Virginia Pulmonary & Critical Care, 1215 Lee Street, 2nd Floor, Charlottesville, VA 22903, USA.

PMID: 37517836
DOI: 10.1016/j.ccm.2023.06.003

Abstract

Interstitial lung disease (ILD), a clinically recognized group of diseases resulting in pulmonary fibrosis, affects up to 200 individuals per 100,000 in the United States. Sarcoidosis has a wide range of clinical manifestations including pulmonary fibrosis. Health disparities are prevalent in both ILD and sarcoidosis around socioeconomic status, race, gender, and geographic location. This review outlines the known health disparities, discusses possible determinants of disparities, and outlines a path to achieve equity in ILD and sarcoidosis.

Keywords: Complex care model; Health disparities; Health equity; Health policy; Interstitial lung disease; Research; Sarcoidosis.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Humans
Idiopathic Pulmonary Fibrosis*
Lung Diseases, Interstitial* / etiology
Lung Diseases, Interstitial* / therapy
Pulmonary Fibrosis*
Sarcoidosis* / epidemiology
Sarcoidosis* / therapy

Abstract

Publication types

MeSH terms

Grants and funding